Rydapt set for EU approval after Novartis addresses CHMP concerns

 
• By Maureen Kenny

Novartis’s new kinase inhibitor, Rydapt (midostaurin), for the treatment of AML and mastocytosis, could have got the thumbs up for EU approval in June but the committee that makes the decision, the European Medicines Agency’s CHMP, had concerns about the application. The CHMP has now issued a positive opinion for the orphan drug and formal EU approval is in sight.

Targets hit in the center by arrows
Rydapt would be first targeted treatment in the EU for certain AML patients • Source: Shutterstock

More from Europe

More from Geography